SOUTH SAN FRANCISCO, CA--(Marketwire - July 31, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK), reported revenues from research and development collaborations of $3.1 million for the second quarter of 2008. Net loss for the second quarter of 2008 was $15.4 million, or $0.31 per share. As of June 30, 2008, cash, cash equivalents, restricted cash and long-term investments totaled $109.8 million.
